S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.07%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.07%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.07%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.07%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

NASDAQ:CNTGCentogene Stock Price, Forecast & News

$12.31
-0.47 (-3.68 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.11
Now: $12.31
$12.75
50-Day Range
$11.55
MA: $16.36
$24.50
52-Week Range
$7.80
Now: $12.31
$28.71
Volume109,100 shs
Average Volume79,110 shs
Market Capitalization$244.49 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene B.V. was founded in 2006 and is headquartered in Rostock, Germany.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNTG
CUSIPN/A
CIKN/A
Phone49-3818-011-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$54.64 million
Book Value$3.32 per share

Profitability

Miscellaneous

Employees400
Market Cap$244.49 million
Next Earnings Date9/21/2020 (Estimated)
OptionableNot Optionable
$12.31
-0.47 (-3.68 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNTG News and Ratings via Email

Sign-up to receive the latest news and ratings for CNTG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Centogene (NASDAQ:CNTG) Frequently Asked Questions

How has Centogene's stock price been impacted by COVID-19?

Centogene's stock was trading at $18.80 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CNTG stock has decreased by 34.5% and is now trading at $12.31.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Centogene?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Centogene in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Centogene
.

When is Centogene's next earnings date?

Centogene is scheduled to release its next quarterly earnings announcement on Monday, September 21st 2020.
View our earnings forecast for Centogene
.

How were Centogene's earnings last quarter?

Centogene N.V. (NASDAQ:CNTG) announced its earnings results on Monday, June, 15th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by $0.10. The firm earned $13.35 million during the quarter, compared to the consensus estimate of $13.78 million.
View Centogene's earnings history
.

What price target have analysts set for CNTG?

4 equities research analysts have issued 1-year target prices for Centogene's stock. Their forecasts range from $17.00 to $23.00. On average, they anticipate Centogene's stock price to reach $20.00 in the next year. This suggests a possible upside of 62.5% from the stock's current price.
View analysts' price targets for Centogene
.

Has Centogene been receiving favorable news coverage?

News coverage about CNTG stock has been trending somewhat negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Centogene earned a media sentiment score of -1.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Centogene
.

Who are some of Centogene's key competitors?

What other stocks do shareholders of Centogene own?

Who are Centogene's key executives?

Centogene's management team includes the following people:
  • Prof. Arndt Rolfs, CEO, Chief Medical Officer & Member of Management Board (Age 60)
  • Mr. Richard Stoffelen, CFO & Member of Management Board (Age 52)
  • Dr. Dirk H. Ehlers, COO, Pres of Clinical Diagnostics & Member of Management Board (Age 58)
  • Dr. Volkmar Weckesser Ph.D., Chief Information Officer & Member of Management Board (Age 52)
  • Prof. Peter Bauer M.D., Chief Scientific Officer (Age 50)

When did Centogene IPO?

(CNTG) raised $60 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Evercore ISI served as the underwriters for the IPO and Baird and BTIG were co-managers.

What is Centogene's stock symbol?

Centogene trades on the NASDAQ under the ticker symbol "CNTG."

Who are Centogene's major shareholders?

Centogene's stock is owned by many different institutional and retail investors. Top institutional shareholders include Platinum Investment Management Ltd. (0.30%), Bank of New York Mellon Corp (0.05%) and New York State Common Retirement Fund (0.03%).

Which major investors are buying Centogene stock?

CNTG stock was acquired by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., Bank of New York Mellon Corp, and New York State Common Retirement Fund.

How do I buy shares of Centogene?

Shares of CNTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Centogene's stock price today?

One share of CNTG stock can currently be purchased for approximately $12.31.

How big of a company is Centogene?

Centogene has a market capitalization of $244.49 million and generates $54.64 million in revenue each year. The company earns $-23,360,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. Centogene employs 400 workers across the globe.

What is Centogene's official website?

The official website for Centogene is www.centogene.com.

How can I contact Centogene?

Centogene's mailing address is AM STRANDE 7, ROSTOCK 2M, 18055. The company can be reached via phone at 49-3818-011-3500 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.